# Total XVII (NCT03117751)

> Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03117751
- Phase: PHASE2, PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: St. Jude Children's Research Hospital
- Conditions: Acute Lymphoblastic Leukemia; Acute Lymphoblastic Lymphoma
- Interventions: Prednisone; Vincristine; Daunorubicin; Pegaspargase; Erwinase®; Cyclophosphamide; Cytarabine; Mercaptopurine; Dasatinib; Methotrexate; Blinatumomab; Ruxolitinib; Bortezomib; Dexamethasone; Doxorubicin; Etoposide; Clofarabine; Vorinostat; Idarubicin; Nelarabine; Thioguanine; Asparaginase Erwinia chrysanthemi (recombinant)-rywn; Calaspargase Pegol
- Enrollment: 790
- Primary outcome: Event-free survival of ALL patients (EFS)
- Primary outcome: Proportion of patients with CEP72TT genotype who develop two or more episodes of Grade 2 or higher neuropathy during Continuation
- Primary outcome: Cumulative incidence of Grade 2 or higher neuropathy in patients with CEP72 CC or CT genotype

## Indexed commentary on Total XVII so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=total-xvii-nct03117751